Metabolic epigenome targeting hits KMT2A-rearranged acute lymphoblastic leukemia by Dirk Heckl, Eva Rettinger

Get full text

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma by Laura M. Moser, Laura M. Moser, Laura M. Moser, Laura M. Moser, Laura M. Moser, Catrin Heim, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Philipp Wendel, Philipp Wendel, Philipp Wendel, Philipp Wendel, Süleyman Bozkurt, Sabine Harenkamp, Hermann Kreyenberg, Hermann Kreyenberg, Michael Merker, Michael Merker, Christian Münch, Christian Münch, Christian Münch, Elise Gradhand, Meike Vogler, Meike Vogler, Meike Vogler, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Halvard Bönig, Halvard Bönig, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Peter Bader, Peter Bader, Peter Bader, Peter Bader, Peter Bader, Winfried S. Wels, Winfried S. Wels, Winfried S. Wels, Eva Rettinger, Eva Rettinger, Eva Rettinger, Eva Rettinger, Eva Rettinger

Get full text

Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation by Catrin Heim, Leonie Hartig, Nadine Weinelt, Laura M. Moser, Emilia Salzmann-Manrique, Michael Merker, Winfried S. Wels, Torsten Tonn, Peter Bader, Jan-Henning Klusmann, Sjoerd J.L. van Wijk, Eva Rettinger

Get full text